Compare CDZI & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CDZI | ASMB |
|---|---|---|
| Founded | 1983 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 444.6M | 414.7M |
| IPO Year | N/A | 2010 |
| Metric | CDZI | ASMB |
|---|---|---|
| Price | $5.25 | $27.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $43.40 |
| AVG Volume (30 Days) | ★ 925.0K | 98.7K |
| Earning Date | 03-27-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $15,979,000.00 | ★ $37,191,000.00 |
| Revenue This Year | $58.18 | $33.33 |
| Revenue Next Year | $32.89 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 188.33 | 31.30 |
| 52 Week Low | $2.13 | $7.75 |
| 52 Week High | $6.96 | $39.71 |
| Indicator | CDZI | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 46.82 | 47.53 |
| Support Level | $4.69 | $25.47 |
| Resistance Level | $5.09 | $27.50 |
| Average True Range (ATR) | 0.38 | 1.77 |
| MACD | -0.04 | 0.29 |
| Stochastic Oscillator | 38.06 | 50.84 |
Cadiz Inc is a water solutions provider, dedicated to delivering clean, reliable, and affordable water for people. It provides water solutions with a combination of land, water, pipeline, and water filtration assets located in Southern California between key water systems serving population centers in the Southwestern United States. The company operates in two reportable segments; Land and Water Resources segment, which derives key revenue, and comprises all activities regarding its properties in the eastern Mojave Desert, pre-revenue development of the Mojave Groundwater Bank (supply, storage, and conveyance), and agricultural operations; and the Water Filtration Technology segment, which provides water filtration solutions for impaired or contaminated groundwater sources.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.